These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 30115088)

  • 1. Development and characterization of an HPV18 detection kit using two novel HPV18 type-specific monoclonal antibodies.
    Zhang Y; He Y; Li L; Liang S; Yan M; Ren D; Yang Z; Zhao W; Miao L; Zhang H; Liu Y
    Diagn Pathol; 2018 Aug; 13(1):55. PubMed ID: 30115088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes.
    Godi A; Boampong D; Elegunde B; Panwar K; Fleury M; Li S; Zhao Q; Xia N; Christensen ND; Beddows S
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32967963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
    J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of codon optimized major capsid protein (L1) of human papillomavirus type 16 and 18 in Pichia pastoris; purification and characterization of the virus-like particles.
    Hanumantha Rao N; Baji Babu P; Rajendra L; Sriraman R; Pang YY; Schiller JT; Srinivasan VA
    Vaccine; 2011 Oct; 29(43):7326-34. PubMed ID: 21803095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of bead-based immunoassay to quantify neutralizing antibody for human papillomavirus 16 and 18.
    Liu HB; Chaturvedi PK; Battogtokh G; Bang HJ; Kim IW; Kim YW; Park KS; Ahn WS
    Mol Biotechnol; 2013 Jun; 54(2):361-70. PubMed ID: 22669586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of HPV58 type-specific antibodies and detection kit.
    Liu Y; Zhang Y; Zhang G; Yang Z; Wang Y; Wu S; Chen D; Zhang H; Liu Y
    Prep Biochem Biotechnol; 2023; 53(2):223-229. PubMed ID: 35465823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting synthetic Human Papillomavirus (HPV) L2 disulfide-induced N-terminus conformational epitopes for pan-HPV vaccine development.
    Khanal S; Ferraris ED; Zahin M; Joh J; Ghim SJ; Jenson AB
    Exp Mol Pathol; 2015 Oct; 99(2):330-4. PubMed ID: 26134615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of two new monoclonal antibodies against human papillomavirus type 16 L1 protein.
    Wang Y; Shang Q; Xu W; Li D; Gu H; Wei L
    Diagn Pathol; 2014 May; 9():101. PubMed ID: 24884993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses.
    Pouyanfard S; Spagnoli G; Bulli L; Balz K; Yang F; Odenwald C; Seitz H; Mariz FC; Bolchi A; Ottonello S; Müller M
    J Virol; 2018 Feb; 92(4):. PubMed ID: 29212932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of an Escherichia coli-derived human papillomavirus type 16 and 18 bivalent vaccine.
    Gu Y; Wei M; Wang D; Li Z; Xie M; Pan H; Wu T; Zhang J; Li S; Xia N
    Vaccine; 2017 Aug; 35(35 Pt B):4637-4645. PubMed ID: 28736197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types.
    Christensen ND; Cladel NM; Reed CA; Budgeon LR; Embers ME; Skulsky DM; McClements WL; Ludmerer SW; Jansen KU
    Virology; 2001 Dec; 291(2):324-34. PubMed ID: 11878901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VLP Production from Recombinant L1/L2 HPV-16 Protein Expressed in Pichia Pastoris.
    Sanchooli A; Aghaiypour K; Kiasari BA; Samarbaf-Zadeh A; Ghadiri A; Makvandi M
    Protein Pept Lett; 2018; 25(8):783-790. PubMed ID: 30091403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human papillomavirus type 58 L1 virus-like particles purified by two-step chromatography elicit high levels of long-lasting neutralizing antibodies.
    Xie X; Liu Y; Zhang T; Xu Y; Bao Q; Chen X; Liu H; Xu X
    Arch Virol; 2013 Jan; 158(1):193-9. PubMed ID: 22965579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix™ in mice.
    Han JE; Wui SR; Park SA; Lee NG; Kim KS; Cho YJ; Kim HJ; Kim HJ
    Vaccine; 2012 Jun; 30(28):4127-34. PubMed ID: 22561312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developments in L2-based human papillomavirus (HPV) vaccines.
    Schellenbacher C; Roden RBS; Kirnbauer R
    Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of type-specific immunoassays to evaluate the functional immune response to Gardasil: a vaccine for human papillomavirus types 16, 18, 6 and 11.
    Smith JF; Kowalski R; Esser MT; Brown MJ; Bryan JT
    Hum Vaccin; 2008; 4(2):134-42. PubMed ID: 18388490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of the mimotopes within the major capsid protein L1 of human papillomavirus types 18 and 45, using neutralizing monoclonal antibodies.
    Li N; Zhang G; Chen Y; Zhou J; Hui C; Li S; Liu H; Liu Y; Qi Y; Wang A
    Int J Biol Macromol; 2021 Mar; 174():587-595. PubMed ID: 33493568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent Neutralizing Humanized Antibody With Topical Therapeutic Potential Against HPV18-Related Cervical Cancer.
    Huang B; Zhu L; Wei H; Shi H; Zhang D; Yuan H; Luan L; Zheng N; Xu S; Nawaz W; Hong Y; Wu X; Wu Z
    Front Immunol; 2021; 12():678318. PubMed ID: 34248960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Papillomavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodies.
    Combelas N; Saussereau E; Fleury MJ; Ribeiro T; Gaitan J; Duarte-Forero DF; Coursaget P; Touzé A
    J Transl Med; 2010 Mar; 8():28. PubMed ID: 20334659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species.
    Gambhira R; Gravitt PE; Bossis I; Stern PL; Viscidi RP; Roden RB
    Cancer Res; 2006 Dec; 66(23):11120-4. PubMed ID: 17145854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.